Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings
- PMID: 35118756
- DOI: 10.1111/ajad.13260
Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings
Abstract
Background: In the United States, an x-waiver credential is necessary to prescribe buprenorphine medication treatment for opioid use disorder (B-MOUD). Historically, this process has required certified training, which could be a barrier to obtaining an x-waiver and subsequently prescribing. To address this barrier, the US recently removed the training requirement for some clinicians. We sought to determine if clinicians who attended x-waiver training went on to obtain an x-waiver and prescribe B-MOUD, and to examine what facilitated or impeded B-MOUD prescribing.
Methods: In September 2020, we conducted a cross-sectional, electronic survey of attendees of 15 in-person x-waiver pieces of training from June 2018 to January 2020 within the Veterans Health Administration (VHA). Of the attendees (n = 321), we surveyed current VHA clinicians who recalled taking the training. The survey assessed whether clinicians obtained the x-waiver, had prescribed B-MOUD, and barriers or facilitators that influenced B-MOUD prescribing.
Results: Of 251 eligible participants, 62 (24.7%) responded to the survey, including 27 (43.5%) physicians, 16 (25.8%) advanced practice clinicians, and 12 (19.4%) pharmacists. Of the 43 clinicians who could prescribe, 29 (67.4%) had obtained their x-waiver and 16 (37.2%) had reported prescribing B-MOUD. Prominent barriers to prescribing B-MOUD included a lack of supporting clinical staff and competing demands on time. The primary facilitator to prescribing was leadership support.
Conclusion and scientific significance: Nine months after x-waiver training, two-thirds of clinicians with prescribing credentials had obtained their x-waiver and one-third were prescribing B-MOUD. Removing the x-waiver training may not have the intended policy effect as other barriers to B-MOUD prescribing persist.
Published 2022. This article is a U.S. Government work and is in the public domain in the USA.
References
REFERENCES
-
- Volkow N, Benveniste H, McLellan AT. Use and misuse of opioids in chronic pain. Annu Rev Med. 2017;69:451-465. doi:10.1146/annurev-med-011817-044739
-
- Volkow ND, Poznyak V, Saxena S, Gerra G. Network U-WIIS. Drug use disorders: impact of a public health rather than a criminal justice approach. World Psychiatry. 2017;16(2):213-214.
-
- Volkow ND. Personalizing the treatment of substance use disorders. Am J Psychiatry. 2020;177(2):113-116. doi:10.1176/appi.ajp.2019.19121284
-
- Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393(10182):1760-1772. doi:10.1016/s0140-6736(18)33078-2
-
- Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377(4):391-394. doi:10.1056/NEJMsr1706626
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical